Do analysts recommend SNGX or PLUR?

Soligenix presently has a consensus price target of $6.00, suggesting a potential upside of 1,500.00%. Given Soligenix's stronger consensus rating and higher possible upside, equities research analysts clearly believe Soligenix is more favorable than Pluri. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Soligenix 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Pluri 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation & earnings, SNGX or PLUR?

Soligenix has higher earnings, but lower revenue than Pluri. Pluri is trading at a lower price-to-earnings ratio than Soligenix, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Soligenix $120K 46.31 -$11.08M -$1.68 N/A Pluri $1.34M 13.82 -$22.58M -$4.53 N/A

Is SNGX or PLUR more profitable?

Soligenix has a net margin of 0.00% compared to Pluri's net margin of -2,162.08%. Pluri's return on equity of 0.00% beat Soligenix's return on equity. Company Net Margins Return on Equity Return on Assets Soligenix N/A -244.73% -131.22% Pluri -2,162.08% N/A -106.59%

Do analysts prefer SNGX or TXMD?

Soligenix currently has a consensus price target of $6.00, indicating a potential upside of 1,500.00%. Given Soligenix's stronger consensus rating and higher possible upside, analysts plainly believe Soligenix is more favorable than TherapeuticsMD. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Soligenix 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer SNGX or VYNE?

Soligenix currently has a consensus target price of $6.00, suggesting a potential upside of 1,500.00%. Given Soligenix's stronger consensus rating and higher probable upside, analysts clearly believe Soligenix is more favorable than VYNE Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Soligenix 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 VYNE Therapeutics 1 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.75

Is SNGX or VYNE more profitable?

Soligenix has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -4,726.21%. VYNE Therapeutics' return on equity of -70.42% beat Soligenix's return on equity. Company Net Margins Return on Equity Return on Assets Soligenix N/A -244.73% -131.22% VYNE Therapeutics -4,726.21% -70.42% -63.46%

Do analysts rate SNGX or ZIVO?

Soligenix currently has a consensus price target of $6.00, indicating a potential upside of 1,500.00%. Given Soligenix's stronger consensus rating and higher probable upside, research analysts clearly believe Soligenix is more favorable than ZIVO Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Soligenix 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 ZIVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is SNGX or ZIVO more profitable?

ZIVO Bioscience's return on equity of 0.00% beat Soligenix's return on equity. Company Net Margins Return on Equity Return on Assets Soligenix N/A -244.73% -131.22% ZIVO Bioscience N/A N/A -2,240.92%

Which has better valuation & earnings, SNGX or KZIA?

Soligenix has higher revenue and earnings than Novogen. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Soligenix $120K 46.31 -$11.08M -$1.68 N/A Novogen $30K 764.72 -$13.41M N/A N/A

Is SNGX or KZIA more profitable?

Novogen's return on equity of 0.00% beat Soligenix's return on equity. Company Net Margins Return on Equity Return on Assets Soligenix N/A -244.73% -131.22% Novogen N/A N/A N/A

Soligenix (SNGX) Competitors

$0.38 +0.01 (+1.38%)

As of 03:03 PM Eastern

Compare

SNGX vs. PLUR, TXMD, VYNE, ZIVO, and KZIA

Should you buy Soligenix stock or one of its competitors? MarketBeat compares Soligenix with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Soligenix include Pluri (PLUR), TherapeuticsMD (TXMD), VYNE Therapeutics (VYNE), ZIVO Bioscience (ZIVO), and Novogen (KZIA). These companies are all part of the "pharmaceutical products" industry.

How does Soligenix compare to Pluri?

Soligenix (NASDAQ:SNGX) and Pluri (NASDAQ:PLUR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

Soligenix has a net margin of 0.00% compared to Pluri's net margin of -2,162.08%. Pluri's return on equity of 0.00% beat Soligenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Soligenix	N/A	-244.73%	-131.22%
Pluri	-2,162.08%	N/A	-106.59%

Soligenix has higher earnings, but lower revenue than Pluri. Pluri is trading at a lower price-to-earnings ratio than Soligenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Soligenix	$120K	46.31	-$11.08M	-$1.68	N/A
Pluri	$1.34M	13.82	-$22.58M	-$4.53	N/A

Soligenix presently has a consensus price target of $6.00, suggesting a potential upside of 1,500.00%. Given Soligenix's stronger consensus rating and higher possible upside, equities research analysts clearly believe Soligenix is more favorable than Pluri.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Soligenix	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Pluri	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Pluri had 2 more articles in the media than Soligenix. MarketBeat recorded 3 mentions for Pluri and 1 mentions for Soligenix. Soligenix's average media sentiment score of 1.87 beat Pluri's score of 0.62 indicating that Soligenix is being referred to more favorably in the media.

Company	Overall Sentiment
Soligenix	Very Positive
Pluri	Positive

Soligenix has a beta of 1.92, meaning that its share price is 92% more volatile than the broader market. Comparatively, Pluri has a beta of 0.64, meaning that its share price is 36% less volatile than the broader market.

3.6% of Soligenix shares are owned by institutional investors. Comparatively, 16.6% of Pluri shares are owned by institutional investors. 3.1% of Soligenix shares are owned by company insiders. Comparatively, 43.2% of Pluri shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Soligenix beats Pluri on 10 of the 16 factors compared between the two stocks.

How does Soligenix compare to TherapeuticsMD?

Soligenix (NASDAQ:SNGX) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, media sentiment, earnings, risk, institutional ownership and valuation.

3.6% of Soligenix shares are held by institutional investors. Comparatively, 30.7% of TherapeuticsMD shares are held by institutional investors. 3.1% of Soligenix shares are held by insiders. Comparatively, 1.7% of TherapeuticsMD shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

TherapeuticsMD has higher revenue and earnings than Soligenix. Soligenix is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Soligenix	$120K	46.31	-$11.08M	-$1.68	N/A
TherapeuticsMD	$3.35M	6.77	-$570K	$0.06	32.67

Soligenix has a beta of 1.92, indicating that its share price is 92% more volatile than the broader market. Comparatively, TherapeuticsMD has a beta of 0.59, indicating that its share price is 41% less volatile than the broader market.

TherapeuticsMD has a net margin of 5.34% compared to Soligenix's net margin of 0.00%. TherapeuticsMD's return on equity of 0.32% beat Soligenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Soligenix	N/A	-244.73%	-131.22%
TherapeuticsMD	5.34%	0.32%	0.23%

Soligenix currently has a consensus price target of $6.00, indicating a potential upside of 1,500.00%. Given Soligenix's stronger consensus rating and higher possible upside, analysts plainly believe Soligenix is more favorable than TherapeuticsMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Soligenix	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Soligenix and Soligenix both had 1 articles in the media. TherapeuticsMD's average media sentiment score of 1.89 beat Soligenix's score of 1.87 indicating that TherapeuticsMD is being referred to more favorably in the news media.

Company	Overall Sentiment
Soligenix	Very Positive
TherapeuticsMD	Very Positive

Summary

TherapeuticsMD beats Soligenix on 9 of the 15 factors compared between the two stocks.

How does Soligenix compare to VYNE Therapeutics?

Soligenix (NASDAQ:SNGX) and VYNE Therapeutics (NASDAQ:VYNE) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk.

Soligenix currently has a consensus target price of $6.00, suggesting a potential upside of 1,500.00%. Given Soligenix's stronger consensus rating and higher probable upside, analysts clearly believe Soligenix is more favorable than VYNE Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Soligenix	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
VYNE Therapeutics	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

3.6% of Soligenix shares are owned by institutional investors. Comparatively, 83.8% of VYNE Therapeutics shares are owned by institutional investors. 3.1% of Soligenix shares are owned by company insiders. Comparatively, 3.0% of VYNE Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Soligenix has a beta of 1.92, meaning that its share price is 92% more volatile than the broader market. Comparatively, VYNE Therapeutics has a beta of 2, meaning that its share price is 100% more volatile than the broader market.

Soligenix has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -4,726.21%. VYNE Therapeutics' return on equity of -70.42% beat Soligenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Soligenix	N/A	-244.73%	-131.22%
VYNE Therapeutics	-4,726.21%	-70.42%	-63.46%

In the previous week, VYNE Therapeutics had 3 more articles in the media than Soligenix. MarketBeat recorded 4 mentions for VYNE Therapeutics and 1 mentions for Soligenix. Soligenix's average media sentiment score of 1.87 beat VYNE Therapeutics' score of 1.15 indicating that Soligenix is being referred to more favorably in the media.

Company	Overall Sentiment
Soligenix	Very Positive
VYNE Therapeutics	Positive

Soligenix has higher earnings, but lower revenue than VYNE Therapeutics. VYNE Therapeutics is trading at a lower price-to-earnings ratio than Soligenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Soligenix	$120K	46.31	-$11.08M	-$1.68	N/A
VYNE Therapeutics	$570K	44.82	-$26.48M	-$0.38	N/A

Summary

Soligenix beats VYNE Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Soligenix compare to ZIVO Bioscience?

Soligenix (NASDAQ:SNGX) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership, media sentiment and risk.

Soligenix has a beta of 1.92, indicating that its stock price is 92% more volatile than the broader market. Comparatively, ZIVO Bioscience has a beta of 0.1, indicating that its stock price is 90% less volatile than the broader market.

ZIVO Bioscience's return on equity of 0.00% beat Soligenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Soligenix	N/A	-244.73%	-131.22%
ZIVO Bioscience	N/A	N/A	-2,240.92%

Soligenix currently has a consensus price target of $6.00, indicating a potential upside of 1,500.00%. Given Soligenix's stronger consensus rating and higher probable upside, research analysts clearly believe Soligenix is more favorable than ZIVO Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Soligenix	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

ZIVO Bioscience has lower revenue, but higher earnings than Soligenix. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Soligenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Soligenix	$120K	46.31	-$11.08M	-$1.68	N/A
ZIVO Bioscience	$15.85K	1,136.89	-$7.78M	-$1.71	N/A

3.6% of Soligenix shares are owned by institutional investors. Comparatively, 12.8% of ZIVO Bioscience shares are owned by institutional investors. 3.1% of Soligenix shares are owned by company insiders. Comparatively, 48.9% of ZIVO Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Soligenix had 1 more articles in the media than ZIVO Bioscience. MarketBeat recorded 1 mentions for Soligenix and 0 mentions for ZIVO Bioscience. Soligenix's average media sentiment score of 1.87 beat ZIVO Bioscience's score of 0.00 indicating that Soligenix is being referred to more favorably in the media.

Company	Overall Sentiment
Soligenix	Very Positive
ZIVO Bioscience	Neutral

Summary

Soligenix beats ZIVO Bioscience on 10 of the 15 factors compared between the two stocks.

How does Soligenix compare to Novogen?

Soligenix (NASDAQ:SNGX) and Novogen (NASDAQ:KZIA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, media sentiment, institutional ownership and earnings.

3.6% of Soligenix shares are owned by institutional investors. Comparatively, 30.9% of Novogen shares are owned by institutional investors. 3.1% of Soligenix shares are owned by insiders. Comparatively, 1.0% of Novogen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Novogen's return on equity of 0.00% beat Soligenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Soligenix	N/A	-244.73%	-131.22%
Novogen	N/A	N/A	N/A

Soligenix has a beta of 1.92, suggesting that its stock price is 92% more volatile than the broader market. Comparatively, Novogen has a beta of 2.14, suggesting that its stock price is 114% more volatile than the broader market.

Soligenix currently has a consensus target price of $6.00, indicating a potential upside of 1,500.00%. Novogen has a consensus target price of $25.80, indicating a potential upside of 85.56%. Given Soligenix's higher possible upside, equities analysts clearly believe Soligenix is more favorable than Novogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Soligenix	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Novogen	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Soligenix has higher revenue and earnings than Novogen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Soligenix	$120K	46.31	-$11.08M	-$1.68	N/A
Novogen	$30K	764.72	-$13.41M	N/A	N/A

In the previous week, Novogen had 2 more articles in the media than Soligenix. MarketBeat recorded 3 mentions for Novogen and 1 mentions for Soligenix. Soligenix's average media sentiment score of 1.87 beat Novogen's score of 0.45 indicating that Soligenix is being referred to more favorably in the media.

Company	Overall Sentiment
Soligenix	Very Positive
Novogen	Neutral

Summary

Novogen beats Soligenix on 8 of the 13 factors compared between the two stocks.

Get Soligenix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SNGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SNGX vs. The Competition

Export

Metric	Soligenix	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.56M	$3.67B	$6.79B	$12.62B
Dividend Yield	N/A	2.19%	2.68%	8.42%
P/E Ratio	-0.22	21.44	27.11	24.33
Price / Sales	46.31	322.28	523.72	90.61
Price / Cash	N/A	143.66	48.59	59.39
Price / Book	0.72	8.58	10.85	6.31
Net Income	-$11.08M	$23.88M	$3.59B	$331.45M
7 Day Performance	1.35%	-2.69%	-1.34%	-0.04%
1 Month Performance	-16.65%	6.07%	2.99%	-0.88%
1 Year Performance	-70.00%	52.66%	28.94%	20.43%

Soligenix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SNGX Soligenix	3.5077 of 5 stars	$0.38 +1.4%	$6.00 +1,500.0%	-72.8%	$5.56M	$120K	N/A	20	Positive News
PLUR Pluri	0.8267 of 5 stars	$2.12 -2.9%	N/A	-66.9%	$22.83M	$1.34M	N/A	150	News Coverage Gap Up
TXMD TherapeuticsMD	1.3164 of 5 stars	$1.97 flat	N/A	+68.4%	$22.79M	$3.02M	32.83	420
VYNE VYNE Therapeutics	1.576 of 5 stars	$0.67 +0.3%	N/A	-46.5%	$22.34M	$570K	N/A	30	Positive News Dividend Announcement
ZIVO ZIVO Bioscience	N/A	$5.25 flat	N/A	-64.2%	$21.80M	$15.85K	N/A	10	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SNGX) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Soligenix (SNGX) Competitors

SNGX vs. PLUR, TXMD, VYNE, ZIVO, and KZIA

How does Soligenix compare to Pluri?

Summary

How does Soligenix compare to TherapeuticsMD?

Summary

How does Soligenix compare to VYNE Therapeutics?

Summary

How does Soligenix compare to ZIVO Bioscience?

Summary

How does Soligenix compare to Novogen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNGX vs. The Competition

Soligenix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Soligenix (SNGX) Competitors

SNGX vs. PLUR, TXMD, VYNE, ZIVO, and KZIA

How does Soligenix compare to Pluri?

Is SNGX or PLUR more profitable?

Which has better valuation & earnings, SNGX or PLUR?

Do analysts recommend SNGX or PLUR?

Does the media favor SNGX or PLUR?

Which has more volatility and risk, SNGX or PLUR?

Do insiders and institutionals hold more shares of SNGX or PLUR?

Summary

How does Soligenix compare to TherapeuticsMD?

Do institutionals and insiders have more ownership in SNGX or TXMD?

Which has better earnings & valuation, SNGX or TXMD?

Which has more volatility & risk, SNGX or TXMD?

Is SNGX or TXMD more profitable?

Do analysts prefer SNGX or TXMD?

Does the media refer more to SNGX or TXMD?

Summary

How does Soligenix compare to VYNE Therapeutics?

Do analysts prefer SNGX or VYNE?

Do insiders & institutionals hold more shares of SNGX or VYNE?

Which has more risk & volatility, SNGX or VYNE?

Is SNGX or VYNE more profitable?

Does the media prefer SNGX or VYNE?

Which has stronger valuation and earnings, SNGX or VYNE?

Summary

How does Soligenix compare to ZIVO Bioscience?

Which has more risk & volatility, SNGX or ZIVO?

Is SNGX or ZIVO more profitable?

Do analysts rate SNGX or ZIVO?

Which has better valuation and earnings, SNGX or ZIVO?

Do institutionals and insiders have more ownership in SNGX or ZIVO?

Does the media refer more to SNGX or ZIVO?

Summary

How does Soligenix compare to Novogen?

Do institutionals & insiders have more ownership in SNGX or KZIA?

Is SNGX or KZIA more profitable?

Which has more volatility and risk, SNGX or KZIA?

Do analysts prefer SNGX or KZIA?

Which has better valuation & earnings, SNGX or KZIA?

Does the media refer more to SNGX or KZIA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNGX vs. The Competition

Soligenix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools